

John D Imig

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7021901/john-d-imig-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

251
papers

9,689
citations

56
h-index

87
g-index

323
ext. papers

10,490
ext. citations

5.1
avg. IF

6.48
L-index

#	Paper	IF	Citations
251	Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. <i>Nature Reviews Drug Discovery</i> , 2009 , 8, 794-805	64.1	458
250	Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. <i>Hypertension</i> , 2002 , 39, 690-4	8.5	345
249	Epoxides and soluble epoxide hydrolase in cardiovascular physiology. <i>Physiological Reviews</i> , 2012 , 92, 101-30	47.9	261
248	Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 5211-6	11.5	207
247	An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. <i>Hypertension</i> , 2005 , 46, 975-81	8.5	205
246	Immune and inflammatory role in renal disease. <i>Comprehensive Physiology</i> , 2013 , 3, 957-76	7.7	185
245	Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006 , 290, H935-40	5.2	183
244	Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. <i>American Journal of Physiology - Renal Physiology</i> , 2005 , 289, F496-503	4.3	183
243	Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 1244-53	12.7	147
242	Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. <i>Hypertension</i> , 2002 , 39, 116-21	8.5	137
241	Identification of a putative microvascular oxygen sensor. <i>Circulation Research</i> , 1996 , 79, 54-61	15.7	137
240	Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats. <i>Hypertension</i> , 1996 , 28, 669-77	8.5	135
239	Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. <i>Journal of Clinical Investigation</i> , 2003 , 112, 1895-905	15.9	131
238	Eicosanoid regulation of the renal vasculature. <i>American Journal of Physiology - Renal Physiology</i> , 2000 , 279, F965-81	4.3	128
237	Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. <i>FASEB Journal</i> , 2010 , 24, 3770-81	0.9	116
236	Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 9038-43	11.5	115
235	Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2009 , 297, F740-8	4.3	109

234	TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008 , 294, R76-83	3.2	108
233	An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. <i>Journal of Cardiovascular Pharmacology</i> , 2005 , 46, 842-8	3.1	106
232	Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. <i>Journal of Vascular Research</i> , 2001 , 38, 247-55	1.9	104
231	Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. <i>Hypertension</i> , 2006 , 47, 557-62	8.5	103
230	Thioredoxin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. <i>Diabetologia</i> , 2014 , 57, 413-23	10.3	102
229	Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. <i>Kidney International</i> , 2000 , 58, 2320-30	9.9	95
228	Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. <i>American Journal of Pathology</i> , 2009 , 174, 2086-95	5.8	93
227	Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. <i>Hypertension</i> , 2003 , 41, 709-14	8.5	92
226	Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. <i>Kidney International</i> , 2007 , 72, 683-9	9.9	88
225	Afferent arteriolar vasodilation to the sulfonimide analog of 11, 12-epoxyeicosatrienoic acid involves protein kinase A. <i>Hypertension</i> , 1999 , 33, 408-13	8.5	87
224	Epoxyeicosatrienoic acid analogs and vascular function. <i>Current Medicinal Chemistry</i> , 2010 , 17, 1181-90	4.3	85
223	Renal uptake of circulating angiotensin II in Val5-angiotensin II infused rats is mediated by AT1 receptor. <i>American Journal of Hypertension</i> , 1998 , 11, 570-8	2.3	84
222	Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 318, 288-95	4.7	81
221	ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. <i>British Journal of Pharmacology</i> , 2005 , 146, 1019-26	8.6	81
220	Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. <i>Hypertension</i> , 2000 , 35, 307-12	8.5	81
219	Anti-inflammatory effects of Ω 3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2013 , 62, 285-97	3.1	78
218	Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. <i>Cardiovascular Drug Reviews</i> , 2006 , 24, 169-88		78
217	Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2496-505	15.9	77

216	Renal accumulation of circulating angiotensin II in angiotensin II-infused rats. <i>Hypertension</i> , 1996 , 27, 658-62	8.5	76
215	Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. <i>Hypertension</i> , 2008 , 51, 352-9	8.5	74
214	Early onset salt-sensitive hypertension in bradykinin B(2) receptor null mice. <i>Hypertension</i> , 1999 , 34, 1768-9	8.0	72
213	Eicosanoids and renal vascular function in diseases. <i>Clinical Science</i> , 2006 , 111, 21-34	6.5	71
212	Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. <i>British Journal of Pharmacology</i> , 1999 , 127, 1399-405	8.6	70
211	Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. <i>Clinical Science</i> , 2009 , 116, 61-70	6.5	69
210	Normalization of the ovarian cancer microenvironment by SPARC. <i>Molecular Cancer Research</i> , 2007 , 5, 1015-30	6.6	69
209	Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. <i>Clinical Science</i> , 2010 , 118, 291-301	6.5	66
208	Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2005 , 288, R188-96	3.2	64
207	Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. <i>Hypertension</i> , 2003 , 42, 594-9	8.5	63
206	Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation. <i>American Journal of Physiology - Renal Physiology</i> , 2014 , 307, F971-80	4.3	62
205	Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2011 , 301, R1307-17	3.2	62
204	Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. <i>Hypertension</i> , 2007 , 50, 1069-76	8.5	62
203	Neuronal nitric oxide synthase modulates rat renal microvascular function. <i>American Journal of Physiology - Renal Physiology</i> , 1998 , 274, F516-24	4.3	61
202	Epoxyeicosatrienoic acids, hypertension, and kidney injury. <i>Hypertension</i> , 2015 , 65, 476-82	8.5	60
201	Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. <i>FASEB Journal</i> , 2013 , 27, 2946-56	0.9	59
200	Afferent and efferent arteriolar vasoconstriction to angiotensin II and norepinephrine involves release of Ca ²⁺ from intracellular stores. <i>Hypertension</i> , 1997 , 29, 222-7	8.5	59
199	Obesity, insulin resistance, and renal function. <i>Microcirculation</i> , 2007 , 14, 349-62	2.9	59

198	Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. <i>Journal of Biological Chemistry</i> , 2008 , 283, 24514-24	5.4	58
197	Renal autoregulation in P2X1 knockout mice. <i>Acta Physiologica Scandinavica</i> , 2004 , 181, 445-53		58
196	Renal endosomes contain angiotensin peptides, converting enzyme, and AT(1A) receptors. <i>American Journal of Physiology - Renal Physiology</i> , 1999 , 277, F303-11	4.3	57
195	Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca ²⁺ -activated K ⁺ Channels. <i>Microcirculation</i> , 2008 , 15, 137-50	2.9	56
194	Fructose stimulates Na/H exchange activity and sensitizes the proximal tubule to angiotensin II. <i>Hypertension</i> , 2014 , 63, e68-73	8.5	55
193	Cytochrome P450 eicosanoids and cerebral vascular function. <i>Expert Reviews in Molecular Medicine</i> , 2011 , 13, e7	6.7	55
192	Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. <i>Clinical Science</i> , 2012 , 122, 513-25	6.5	54
191	Cyclooxygenase-2 modulates afferent arteriolar responses to increases in pressure. <i>Hypertension</i> , 1999 , 34, 843-7	8.5	54
190	Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. <i>Clinical Science</i> , 2014 , 127, 463-74	6.5	52
189	Increased blood pressure in mice lacking cytochrome P450 2J5. <i>FASEB Journal</i> , 2008 , 22, 4096-108	0.9	52
188	Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. <i>Journal of Hypertension</i> , 2001 , 19, 983-92	1.9	52
187	Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. <i>American Journal of Pathology</i> , 2007 , 171, 1104-12	5.8	51
186	Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function. <i>Advances in Pharmacology</i> , 2016 , 77, 105-41	5.7	51
185	Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor α agonist improve vascular function and decrease renal injury in hypertensive obese rats. <i>Experimental Biology and Medicine</i> , 2012 , 237, 1402-12	3.7	50
184	SPARC ameliorates ovarian cancer-associated inflammation. <i>Neoplasia</i> , 2008 , 10, 1092-104	6.4	50
183	Unraveling the Mystery of Goldblatt Hypertension. <i>Physiology</i> , 1998 , 13, 170-176	9.8	50
182	Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. <i>Prostaglandins and Other Lipid Mediators</i> , 2013 , 104-105, 2-7	3.7	49
181	Targeting epoxides for organ damage in hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2010 , 56, 329-35	3.1	49

180	Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 308, F131-9	4.3	47
179	Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat. <i>Hypertension</i> , 2013 , 62, 905-13	8.5	47
178	Role of renal nerves in afferent arteriolar reactivity in angiotensin-induced hypertension. <i>Hypertension</i> , 1997 , 29, 442-9	8.5	46
177	Eicosanoids and renal damage in cardiometabolic syndrome. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 165-74	5.5	46
176	The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt. <i>Journal of Biological Chemistry</i> , 2014 , 289, 4377-86	5.4	45
175	PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006 , 290, H2187-95	5.2	44
174	Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. <i>Frontiers in Physiology</i> , 2010 , 1, 157	4.6	43
173	Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. <i>Pharmacology & Therapeutics</i> , 2018 , 192, 1-19	13.9	43
172	Glomerular expression of kidney injury molecule-1 and podocytopenia in diabetic glomerulopathy. <i>American Journal of Nephrology</i> , 2011 , 34, 268-80	4.6	41
171	Protein phosphatase 2A and Ca ²⁺ -activated K ⁺ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. <i>Prostaglandins and Other Lipid Mediators</i> , 2007 , 83, 50-61	3.7	41
170	Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. <i>Obesity</i> , 2004 , 12, 1278-89		41
169	12-Hydroxyeicosatetraenoic acid participates in angiotensin II afferent arteriolar vasoconstriction by activating L-type calcium channels. <i>Journal of Lipid Research</i> , 2003 , 44, 2391-9	6.3	41
168	Contribution of prostaglandin EP(2) receptors to renal microvascular reactivity in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2002 , 283, F415-22	4.3	41
167	Rofecoxib decreases renal injury in obese Zucker rats. <i>Clinical Science</i> , 2004 , 107, 561-70	6.5	40
166	Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. <i>American Journal of Hypertension</i> , 2000 , 13, 810-8	2.3	40
165	Interactive nitric oxide-angiotensin II influences on renal microcirculation in angiotensin II-induced hypertension. <i>Hypertension</i> , 1998 , 31, 1255-60	8.5	40
164	Purinoreceptor-mediated calcium signaling in preglomerular smooth muscle cells. <i>Hypertension</i> , 1999 , 33, 195-200	8.5	40
163	Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, F86-94	4.3	39

162	The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001 , 281, H2089-96	5.2	39
161	Calcium signaling pathways utilized by P2X receptors in freshly isolated preglomerular MVSMC. <i>American Journal of Physiology - Renal Physiology</i> , 2001 , 280, F1054-61	4.3	39
160	Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: interaction with neuronal NOS. <i>American Journal of Physiology - Renal Physiology</i> , 1998 , 275, F605-12	4.3	39
159	Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 318, 1307-14	4.7	38
158	Novel nitric oxide synthase--dependent mechanism of vasorelaxation in small arteries from hypertensive rats. <i>Hypertension</i> , 2007 , 49, 893-901	8.5	38
157	Calcium mobilization contributes to pressure-mediated afferent arteriolar vasoconstriction. <i>Hypertension</i> , 1998 , 31, 421-8	8.5	38
156	Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. <i>Clinical Science</i> , 2010 , 118, 617-32	6.5	37
155	Endothelin-mediated calcium signaling in preglomerular smooth muscle cells. <i>Hypertension</i> , 2000 , 35, 280-6	8.5	37
154	Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. <i>European Journal of Pharmacology</i> , 2009 , 607, 143-50	5.3	36
153	ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses: EDHF Involvement. <i>Hypertension</i> , 2004 , 43, 533-5	8.5	36
152	Renal AT1 receptor protein expression during the early stage of diabetes mellitus. <i>International Journal of Experimental Diabetes Research</i> , 2002 , 3, 97-108		36
151	Impaired Ca ²⁺ signaling attenuates P2X receptor-mediated vasoconstriction of afferent arterioles in angiotensin II hypertension. <i>Hypertension</i> , 2005 , 46, 562-8	8.5	36
150	Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 597-610	12.7	35
149	Epoxygenase metabolites. Epithelial and vascular actions. <i>Molecular Biotechnology</i> , 2000 , 16, 233-51	3	35
148	Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. <i>Hypertension</i> , 2005 , 46, 366-71	8.5	34
147	Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. <i>Hypertension</i> , 2003 , 42, 775-80	8.5	33
146	Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. <i>Vascular Pharmacology</i> , 2007 , 47, 145-59	5.9	32
145	A dual COX-2/SEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. <i>Prostaglandins and Other Lipid Mediators</i> , 2016 , 125, 40-7	3.7	31

144	Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. <i>Journal of Physiology</i> , 2011 , 589, 207-19	3.9	31
143	Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014 , 41, 227-37	3	30
142	Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2011 , 300, R1468-75	3.2	30
141	Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006 , 290, R435-41	3.2	30
140	Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. <i>Journal of Hypertension</i> , 2011 , 29, 1590-601	1.9	29
139	P2X receptor-stimulated calcium responses in preglomerular vascular smooth muscle cells involves 20-hydroxyeicosatetraenoic acid. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 311, 1211-7	4.7	29
138	Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation. <i>Journal of Hypertension</i> , 2004 , 22, 811-8	1.9	28
137	p66Shc regulates renal vascular tone in hypertension-induced nephropathy. <i>Journal of Clinical Investigation</i> , 2016 , 126, 2533-46	15.9	28
136	Orally Active Epoxyeicosatrienoic Acid Analogs. <i>Journal of Cardiovascular Pharmacology</i> , 2017 , 70, 211-234	3.4	27
135	A novel dual PPAR- δ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. <i>Diabetologia</i> , 2018 , 61, 2235-2246	10.3	27
134	Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury. <i>Frontiers in Pharmacology</i> , 2014 , 5, 216	5.6	27
133	L-type calcium channels in the renal microcirculatory response to endothelin. <i>American Journal of Physiology - Renal Physiology</i> , 2005 , 288, F771-7	4.3	26
132	Heterogeneous activation mechanisms in the renal microvasculature. <i>Kidney International</i> , 1998 , 67, S17-21	3.1	25
131	Neuronal nitric oxide synthase-dependent afferent arteriolar function in angiotensin II-induced hypertension. <i>Hypertension</i> , 1999 , 33, 462-6	8.5	25
130	Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans. <i>Diabetologia</i> , 2017 , 60, 1066-1075	10.3	24
129	14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 6965-72	8.3	24
128	Calcium and chloride channel activation by angiotensin II-AT1 receptors in preglomerular vascular smooth muscle cells. <i>American Journal of Physiology - Renal Physiology</i> , 2005 , 289, F760-7	4.3	24
127	Obesity induced renal oxidative stress contributes to renal injury in salt-sensitive hypertension. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2009 , 36, 724-8	3	23

126	Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. <i>Kidney and Blood Pressure Research</i> , 2012 , 35, 595-607	3.1	23
125	Epoxyeicosatrienoic Acid Analog Decreases Renal Fibrosis by Reducing Epithelial-to-Mesenchymal Transition. <i>Frontiers in Pharmacology</i> , 2017 , 8, 406	5.6	22
124	Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. <i>American Journal of Hypertension</i> , 2011 , 24, 816-21	2.3	22
123	Increased renal proximal convoluted tubule transport contributes to hypertension in Cyp4a14 knockout mice. <i>Nephron Physiology</i> , 2009 , 113, p23-8		21
122	The Renal Microcirculation 2008 , 550-683		20
121	Postglomerular vasoconstriction to angiotensin II and norepinephrine depends on intracellular calcium release. <i>General Pharmacology</i> , 2000 , 34, 409-15		20
120	Novel Omega-3 Fatty Acid Epoxygenase Metabolite Reduces Kidney Fibrosis. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	20
119	Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy. <i>Clinical Science</i> , 2016 , 130, 587-99	6.5	20
118	Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 1326-1341	1.9	19
117	Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017 , 1861, 2758-2765	4	19
116	Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. <i>FASEB Journal</i> , 2006 , 20, 539-41	0.9	19
115	Age-related alterations in NOS and oxidative stress in mesenteric arteries from male and female rats. <i>Journal of Applied Physiology</i> , 2004 , 97, 1268-74	3.7	19
114	Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2012 , 39, 454-61	3	18
113	Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. <i>Journal of Hypertension</i> , 2013 , 31, 321-32	1.9	18
112	Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. <i>Journal of Hypertension</i> , 2010 , 28, 582-93	1.9	18
111	Epoxyeicosanoids in hypertension. <i>Physiological Research</i> , 2019 , 68, 695-704	2.1	18
110	Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats. <i>Journal of Hypertension</i> , 2016 , 34, 2008-25	1.9	17
109	Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. <i>Cardiovascular Drugs and Therapy</i> , 2014 , 28, 313-22	3.9	17

108	Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013 , 40, 273-81	3	17
107	The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension. <i>Pharmaceuticals</i> , 2009 , 2, 217-227	5.2	17
106	IL6 suppression provides renal protection independent of blood pressure in a murine model of salt-sensitive hypertension. <i>Kidney and Blood Pressure Research</i> , 2007 , 30, 195-202	3.1	17
105	Adaptations of the Renal Microcirculation to Hypertension. <i>Microcirculation</i> , 2002 , 9, 315-328	2.9	17
104	Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014 , 41, 1003-13	3	16
103	11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 302, H1574-83	5.2	16
102	The Bradykinin B2 receptor is required for full expression of renal COX-2 and renin. <i>Peptides</i> , 2003 , 24, 1141-7	3.8	16
101	Cytochrome P450 and Lipoxygenase Metabolites on Renal Function. <i>Comprehensive Physiology</i> , 2015 , 6, 423-41	7.7	15
100	Tumour necrosis factor- α contributes to improved cardiac ischaemic tolerance in rats adapted to chronic continuous hypoxia. <i>Acta Physiologica</i> , 2015 , 214, 97-108	5.6	14
99	The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, F576-85	4.3	14
98	A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. <i>Biochemical Pharmacology</i> , 2019 , 166, 212-221	6	13
97	20-HETE or EETs: which arachidonic acid metabolite regulates proximal tubule transporters and contributes to pressure natriuresis?. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2004 , 287, R3-5	3.2	13
96	ATP-mediated Ca ²⁺ signaling in preglomerular smooth muscle cells. <i>American Journal of Physiology - Renal Physiology</i> , 1999 , 276, F450-6	4.3	13
95	Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. <i>Clinical Science</i> , 2019 , 133, 939-951	6.5	12
94	Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1 α via downregulation of prolyl hydroxylase 3. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018 , 315, H1148-H1158	5.2	12
93	Azilsartan improves glycemic status and reduces kidney damage in Zucker diabetic fatty rats. <i>American Journal of Hypertension</i> , 2014 , 27, 1087-95	2.3	12
92	Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors. <i>PPAR Research</i> , 2010 , 2010, 703735	4.3	12
91	Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension. <i>Vascular Pharmacology</i> , 2007 , 46, 144-51	5.9	12

90	Eicosanoid blood vessel regulation in physiological and pathological states. <i>Clinical Science</i> , 2020 , 134, 2707-2727	6.5	12
89	Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. <i>Vascular Pharmacology</i> , 2015 , 73, 45-56	5.9	11
88	Multi-Target Approaches in Metabolic Syndrome. <i>Frontiers in Pharmacology</i> , 2020 , 11, 554961	5.6	11
87	Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Transgenic Rats. <i>Frontiers in Pharmacology</i> , 2019 , 10, 159	5.6	10
86	Epoxyeicosatrienoic Acid Analog EET-A Blunts Development of Lupus Nephritis in Mice. <i>Frontiers in Pharmacology</i> , 2019 , 10, 512	5.6	9
85	Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture. <i>Hypertension</i> , 2020 , 76, 3-15	8.5	9
84	Inactivation of p66Shc Decreases Afferent Arteriolar K Channel Activity and Decreases Renal Damage in Diabetic Dahl SS Rats. <i>Diabetes</i> , 2018 , 67, 2206-2212	0.9	9
83	Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure. <i>Kidney and Blood Pressure Research</i> , 2019 , 44, 792-809	3.1	9
82	The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. <i>Kidney and Blood Pressure Research</i> , 2007 , 30, 335-46	3.1	9
81	CYP450, COX-2 and Obesity Related Renal Damage. <i>Toxicology Mechanisms and Methods</i> , 2005 , 15, 125-366	3.6	9
80	Adaptations of the renal microcirculation to hypertension. <i>Microcirculation</i> , 2002 , 9, 315-28	2.9	9
79	Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension. <i>Purinergic Signalling</i> , 2015 , 11, 519-31	3.8	8
78	Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. <i>Kidney and Blood Pressure Research</i> , 2018 , 43, 329-349	3.1	8
77	Regulation of Cardiac Mast Cell Maturation and Function by the Neurokinin-1 Receptor in the Fibrotic Heart. <i>Scientific Reports</i> , 2019 , 9, 11004	4.9	8
76	20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. <i>Bioscience Reports</i> , 2018 , 38,	4.1	8
75	Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats. <i>Frontiers in Pharmacology</i> , 2019 , 10, 18	5.6	7
74	Dual soluble epoxide hydrolase inhibitor/PPAR- δ agonist attenuates renal fibrosis. <i>Prostaglandins and Other Lipid Mediators</i> , 2020 , 150, 106472	3.7	7
73	Role of the cytochrome P-450/ epoxyeicosatrienoic acids pathway in the pathogenesis of renal dysfunction in cirrhosis. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1333-1343	4.3	7

72	Afferent Arteriolar Responses to β -methylene ATP and 20-HETE are not Blocked by ENaC Inhibition. <i>Physiological Reports</i> , 2013 , 1, e00082	2.6	7
71	Interlobular Arteries From 2-Kidney, 1-Clip Goldblatt Hypertensive Rats Exhibit Impaired Vasodilator Response to Epoxyeicosatrienoic Acids. <i>American Journal of the Medical Sciences</i> , 2016 , 351, 513-9	2.2	7
70	The Renal Microcirculation 2008 , 550-683		6
69	Combined treatment with epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid antagonist provides substantial hypotensive effect in spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 2020 , 38, 1802-1810	1.9	6
68	Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles. <i>American Journal of Physiology - Renal Physiology</i> , 2011 , 301, F765-72	4.3	4
67	Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
66	Radiation-induced afferent arteriolar endothelial-dependent dysfunction involves decreased epoxygenase metabolites. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016 , 310, H1695-701	5.2	3
65	Epoxylipids and soluble epoxide hydrolase in heart diseases. <i>Biochemical Pharmacology</i> , 2021 , 195, 114866		3
64	Physiological roles of soluble epoxide hydrolase and therapeutic prospects of its inhibition. <i>FASEB Journal</i> , 2006 , 20,	0.9	3
63	Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats. <i>Frontiers in Physiology</i> , 2021 , 12, 622882	4.6	3
62	20-hydroxyeicosatetraenoic acid and angiotensin: a positive feedback system to cause hypertension. <i>Hypertension</i> , 2010 , 56, 822-3	8.5	2
61	Adenosine _{2A} receptors and epoxyeicosatrienoic acids: a recipe for salt and blood pressure regulation. <i>Hypertension</i> , 2009 , 54, 1223-5	8.5	2
60	THE EFFECT OF COMPOUND DM509 ON KIDNEY FIBROSIS IN THE CONDITIONS OF THE EXPERIMENTAL MODEL. <i>Bulletin of Taras Shevchenko National University of Kyiv Series Biology</i> , 2020 , 80, 10-15	0.2	2
59	Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. <i>Current Opinion in Nephrology and Hypertension</i> , 2022 , 31, 36-46	3.5	2
58	Ether epoxyeicosatrienoic acid (EET) analogs lower blood pressure when administered in-vivo to the spontaneously hypertensive rats. <i>FASEB Journal</i> , 2008 , 22, 479.44	0.9	2
57	Molecular Pathways in Hypertensive Renal Damage. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018 , 445-463	0.1	2
56	Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats. <i>British Journal of Pharmacology</i> , 2021 , 178, 4468-4484	8.6	2
55	SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection.. <i>Clinical Science</i> , 2022 , 136, 431-434	6.5	2

54	Dual sEH/COX-2 Inhibition Using PTUPB-A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 744776	5.6	2
53	Mitigation of normal tissue radiation injury: evidence from rat radiation nephropathy models. <i>Journal of Radiation Oncology</i> , 2016 , 5, 1-8	0.7	1
52	Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease. <i>Current Enzyme Inhibition</i> , 2006 , 2, 73-77	0.5	1
51	Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 798642	5.6	1
50	Elevated Aminopeptidase P Attenuates Cerebral Arterial Responses to Bradykinin in Fawn-Hooded Hypertensive Rats. <i>PLoS ONE</i> , 2015 , 10, e0145335	3.7	1
49	A SORAFENIB INDUCED MODEL OF GLOMERULAR KIDNEY DISEASE. <i>Bulletin of Taras Shevchenko National University of Kyiv Series Biology</i> , 2020 , 81, 25-31	0.2	1
48	Urea-based soluble epoxide hydrolase inhibitors dilate mesenteric resistance vessels. <i>FASEB Journal</i> , 2006 , 20, A669	0.9	1
47	Soluble Epoxide Hydrolase Inhibition Modulates Gene Expression of Anti-Apoptotic and Apoptotic Factors. <i>FASEB Journal</i> , 2008 , 22, 733.11	0.9	1
46	A Dual Soluble Epoxide Hydrolase Inhibitor/PPAR- α Agonist Prevents Renal Fibrosis in Mouse Unilateral Ureteral Obstruction Model. <i>FASEB Journal</i> , 2019 , 33, 678.12	0.9	1
45	Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. <i>Kidney and Blood Pressure Research</i> , 2019 , 44, 1493-1505	3.1	1
44	Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation. <i>Biomedicines</i> , 2021 , 9,	4.8	1
43	Diabetes risk associated with plasma epoxy lipid levels. <i>EBioMedicine</i> , 2021 , 66, 103331	8.8	0
42	Loss of Chloride Channel 6 (CLC-6) Affects Vascular Smooth Muscle Contractility and Arterial Stiffness via Alterations to Golgi Calcium Stores. <i>Hypertension</i> , 2021 , 77, 582-593	8.5	0
41	Multi-Target Drugs for Kidney Diseases.. <i>Kidney360</i> , 2021 , 2, 1645-1653	1.8	0
40	Reply to "Letter to the editor: Concern regarding quantification of urinary nephrin by commercially available ELISA". <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 309, F271	4.3	
39	REVERSAL OF UNILATERAL URETERAL OBSTRUCTION LEADS TO SALT-SENSITIVE HYPERTENSION. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
38	DUAL ACTING COX-2 AND SOLUBLE EPOXIDE HYDROLASE INHIBITOR ATTENUATES GLOMERULAR INJURY IN FOCAL SEGMENTAL GLOMERULAR SCLEROSIS. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
37	Effective Antihypertensive Treatment with Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Antagonist (AAA) of Spontaneously Hypertensive Rats (SHR). <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	

36	A DUAL COX-2/sEH INHIBITOR TREATED KIDNEY INJURY IN A DRUG-INDUCED GLOMERULAR DISEASE MODEL. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9
35	Fructose Consumption Increases Blood Pressure and Induces Changes in Renal Microvascular Function. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9
34	Tim-1 Deficiency Aggravates High-Fat Diet-Induced Steatohepatitis in Mice. <i>Frontiers in Immunology</i> , 2021 , 12, 747794	8.4
33	Dietary fat increases renal injury in SHR in the absence of changes in insulin sensitivity or blood pressure. <i>FASEB Journal</i> , 2007 , 21, A1194	0.9
32	Rosaglitazone (RGZ) decreases renal damage in spontaneously diabetic Goto-Kakizaki (GK) rats. <i>FASEB Journal</i> , 2007 , 21, A1194	0.9
31	Peroxisome proliferators-activated receptor-alpha activation increases renal CYP2C23 and decreases cyclin D1 and blood pressure in Zucker diabetic fatty rats. <i>FASEB Journal</i> , 2007 , 21, A842	0.9
30	Long-term high fat diet treatment activates NF kappa B signaling and increases endothelial dysfunction in angiotensin II hypertensive rats. <i>FASEB Journal</i> , 2007 , 21, A1196	0.9
29	High fat diet induces insulin resistance and heightened renal inflammation in angiotensin II hypertensive rats. <i>FASEB Journal</i> , 2007 , 21, A504	0.9
28	Soluble Epoxide Inhibition Differentially Modulates Flow Induced Vascular Remodeling in Spontaneously Hypertensive Stroke Prone Rats and Wistar Kyoto Rats. <i>FASEB Journal</i> , 2008 , 22, 479.42	0.9
27	Soluble epoxide hydrolase inhibition attenuates the development of renovascular hypertension in 2K1C rats.. <i>FASEB Journal</i> , 2008 , 22, 479.7	0.9
26	Simvastatin and Tempol Protect Against Endothelial Dysfunction and Renal Injury in a Model of Obesity and Hypertension. <i>FASEB Journal</i> , 2008 , 22, 947.8	0.9
25	Soluble epoxide hydrolase inhibitor improves cardiac ischemic tolerance in Ren-2 transgenic rats. <i>FASEB Journal</i> , 2008 , 22, 479.6	0.9
24	The divergent role of epoxyeicosatrienoic acids in the regulation of renal function in normotensive and two-kidney one-clip Goldblatt hypertensive rats. <i>FASEB Journal</i> , 2008 , 22, 761.1	0.9
23	The Effect of Voltage-Sensitive Chloride Channel 6 on Development of Salt-Sensitive Hypertension. <i>FASEB Journal</i> , 2018 , 32, 750.23	0.9
22	Glomerular Mesangial Proliferation is Mitigated by sEH/COX-2 Dual-Inhibition. <i>FASEB Journal</i> , 2019 , 33, 671.7	0.9
21	A Dual Farnesoid X Receptor Agonist /Soluble Epoxide Hydrolase Inhibitor Prevents Non-Alcoholic Steatohepatitis in Mice. <i>FASEB Journal</i> , 2019 , 33, 506.3	0.9
20	EET Analogs and the Dual-Inhibition of sEH/COX-2 for the Treatment of Focal Segmental Glomerular Sclerosis. <i>FASEB Journal</i> , 2019 , 33, 863.8	0.9
19	A Novel Dual Soluble Epoxide Hydrolase Inhibitor/Cyclooxygenase-2 Inhibitor Treats Type 2 Diabetic Complications in Obese ZSF1 Rats. <i>FASEB Journal</i> , 2019 , 33, 514.2	0.9

18	COMBINED FARNESOID X RECEPTOR AGONIST AND SOLUBLE EPOXIDE HYDROLASE INHIBITOR TREATS PROGRESSIVE RENAL FIBROSIS. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9
17	A dual COX-sEH inhibitor improved glycemic status and reduced kidney injury in Zucker diabetic fatty rat (689.4). <i>FASEB Journal</i> , 2014 , 28, 689.4	0.9
16	Radiation Nephropathy is Mitigated by Epoxyeicosatrienoic acid Analog. <i>FASEB Journal</i> , 2015 , 29, 938.4	0.9
15	SPARC deficiency ameliorates renal damage resulting from angiotensin II and a high salt diet. <i>FASEB Journal</i> , 2009 , 23, 604.1	0.9
14	Renal mechanisms of antihypertensive effects caused by inhibition of soluble epoxide hydrolase in Cyp1a1-Ren-2 transgenic rats.. <i>FASEB Journal</i> , 2009 , 23, 1016.4	0.9
13	LC-MS measurement of the epoxyeicosatrienoic acid mimetic EET-8-ZE-D in rat serum. <i>FASEB Journal</i> , 2009 , 23, 1019.13	0.9
12	Development of combined soluble epoxide hydrolase inhibitors and epoxide analogs with vasodilator activity. <i>FASEB Journal</i> , 2009 , 23, 766.2	0.9
11	Epoxyeicosatrienoic acids (EET) contribute to flow-induced dilation in mice mesenteric resistance artery. <i>FASEB Journal</i> , 2009 , 23, 932.1	0.9
10	Impaired mesenteric resistance artery relaxation to KATP channel activation in cardiometabolic syndrome is improved by rosiglitazone treatment. <i>FASEB Journal</i> , 2010 , 24, 978.9	0.9
9	Soluble Epoxide Hydrolase Inhibition (SEHi) and Thiazolidinedione (TZD) in combination provide greater renal injury protection in Spontaneously Hypertensive Obese (SHROB) Rats.. <i>FASEB Journal</i> , 2010 , 24, 812.9	0.9
8	Attenuated endothelin-1 (ET-1) vasoconstrictor responses in cardiometabolic syndrome are attributed to increased ET-B receptors. <i>FASEB Journal</i> , 2010 , 24, 978.10	0.9
7	Vascular Endothelial Growth Factor (VEGF) Inhibitors Induce Hypertension, Afferent Arteriolar Dysfunction, and Glomerular Injury. <i>FASEB Journal</i> , 2010 , 24, 575.9	0.9
6	CYP Pathway Modulators Alter Development and Angiogenesis in Zebrafish Embryos. <i>FASEB Journal</i> , 2011 , 25, lb437	0.9
5	Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. <i>FASEB Journal</i> , 2011 , 25, 664.10	0.9
4	Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance.. <i>FASEB Journal</i> , 2012 , 26, 686.4	0.9
3	Novel Orally Active Epoxyeicosatrienoic Acid (EET) Analogs Attenuate Cisplatin Nephrotoxicity. <i>FASEB Journal</i> , 2012 , 26, 851.7	0.9
2	A novel epoxyeicosatrienoic acid analog attenuates hypertension and renal injury in Cyp2c44 KO mice. <i>FASEB Journal</i> , 2013 , 27, 880.1	0.9
1	SP074SOLUBLE EPOXIDE HYDROLASE INHIBITION AUGMENTS RAS BLOCKADE RENOPROTECTION INSUBTOTALLY NEPHRECTOMIZED REN-2 TRANSGENIC HYPERTENSIVE RATS WITH CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i370-i370	4.3

